RxDoctor Payments Data

Dung Nguyen, MD

Neurology · Arlington, TXNPI 1801828363

Payments from drug & device makers

$13,553in general payments, 2019–2025

Across 694 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$3K
  • Amgen$748
  • AbbVie$744
  • UCB, Inc.$680
  • Novartis$680
  • Teva Pharmaceuticals USA, Inc.$597
  • plus $7K from 52 others

What the payments were for

  • Speaking & faculty fees$1081%
  • Food & beverage$13,26498%
  • Education$1821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.154$2,735
Amgen(2 entities)37$748
AbbVie(2 entities)41$744
UCB, Inc.29$680
Novartis35$680
Teva Pharmaceuticals USA, Inc.36$597
Biogen33$557
Lilly USA, LLC26$510
Lundbeck LLC21$397
Eisai Inc.17$324
Kyowa Kirin, Inc.13$323
AstraZeneca15$304
Pfizer14$287
Amneal Pharmaceuticals LLC15$275
Grifols USA, LLC13$261
Jazz Pharmaceuticals Inc.11$258
Acorda Therapeutics, Inc12$257
Harmony Biosciences LLC6$243
Sanofi7$236
Argenx US, Inc.9$204
Otsuka America Pharmaceutical, Inc.5$204
Johnson & Johnson15$191
Upsher-smith Laboratories LLC10$188
Adamas Pharmaceuticals, Inc.10$186
SK Life Science, Inc.9$181
Supernus Pharmaceuticals, Inc.11$174
Avion Pharmaceuticals8$164
Biohaven Pharmaceutical Holding Company Ltd.5$121
CSL Behring5$115
Boston Scientific4$104
Biohaven Pharmaceuticals, Inc.6$102
Acadia Pharmaceuticals Inc5$98
Genentech USA, Inc.5$97
Neurocrine Biosciences, Inc.4$81
TG Therapeutics, Inc.4$79
Xeris Pharmaceuticals, Inc.4$77
Bristol Myers Squibb4$74
Abbott4$74
MDD US Operations, LLC3$71
GE HealthCare3$59
Axsome Therapeutics, Inc.2$57
Avanir Pharmaceuticals, Inc.4$56
Neurelis, Inc.3$53
Mallinckrodt Hospital Products Inc.1$36
Octapharma USA, Inc.1$35
Takeda Pharmaceuticals U.S.A., Inc.1$33
Arbor Pharmaceuticals, Inc.2$28
Aprecia Pharmaceuticals, LLC2$26
Vertical Pharmaceuticals, LLC1$22
Nevro Corp.1$21
Assertio Therapeutics, Inc.1$18
Currax Pharmaceuticals LLC1$18
C2n Diagnostics, LLC1$17
Catalyst Pharmaceuticals, Inc.1$17
Cycle Pharmaceuticals Inc1$16
Corium, LLC1$16
Aucta Pharmaceuticals, Inc.1$14
Sunovion Pharmaceuticals Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,553 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$117,257
Medicare patients
265
Services billed
3,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin13$159,130
Avonex Pen (4 Pack)Interferon Beta-1a13$111,266
Aimovig AutoinjectorErenumab-Aooe19$35,585
BotoxOnabotulinumtoxina22$28,607
NamzaricMemantine Hcl/Donepezil Hcl22$26,154
Oxtellar XrOxcarbazepine13$17,264
Rivastigmine52$11,710
Memantine Hcl396$11,029
Dalfampridine ErDalfampridine13$5,968
Gabapentin186$5,534
RivastigmineRivastigmine Tartrate82$5,497
Primidone130$4,602
Carbidopa-Levodopa ErCarbidopa/Levodopa77$4,372
Carbamazepine ErCarbamazepine28$4,229
Levetiracetam112$4,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Namzaric$744$54,76144 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$174$17,26413 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$275$1,53916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.

Other neurology in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →